| Clinical data | |
|---|---|
| Trade names | Oxybral SR |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.015.070 |
| Chemical and physical data | |
| Formula | C21H26N2O3 |
| Molar mass | 354.450 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Vincamine is a monoterpenoid indole alkaloid found in the leaves of Vinca minor (lesser periwinkle), comprising about 25–65% of its indole alkaloids by weight. It can also be synthesized from related alkaloids.
Vincamine is sold in Europe as a prescription medicine for the treatment of primary degenerative and vascular dementia.[citation needed] In the United States, it is permitted to be sold as a dietary supplement when labeled for use in adults for six months or less. Most common preparations are in the sustained release tablet forms.
Tabersonine can be used for semi-synthesis of vincamine.
Vinpocetine is a synthetic derivative of vincamine used for cerebrovascular diseases and as dietary supplement. Vincamine derivatives have been also studied as anti addictive and antidiabetic agents.
It may have nootropic effects. It has been investigated as novel anticancer drug.
Concerns over long-term use have been documented by the US National Toxicology Program.